Cargando…

Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial

INTRODUCTION: Japanese encephalitis (JE) virus is one of the leading causes of viral encephalitis across temperate and tropical zones of Asia. The live attenuated SA 14-14-2 JE vaccine (CD-JEV) is one of three vaccines prequalified by the World Health Organization (WHO) to prevent JE. WHO currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaman, K., Yunus, Md., Aziz, Asma B., Feser, Jodi, Mooney, Jessica, Tang, Yuxiao, Ellison, Damon W., Thaisomboonsuk, Butsaya, Zhang, Lei, Neuzil, Kathleen M., Marfin, Anthony A., Letson, G. William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Regular paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857502/ https://www.ncbi.nlm.nih.gov/pubmed/35243320 http://dx.doi.org/10.1016/j.jvacx.2022.100143

Ejemplares similares

Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9–12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial
por: Capeding, Maria Rosario, et al.
Publicado: (2020)

Effectiveness of the SA 14-14-2 Live-Attenuated Japanese Encephalitis Vaccine in Myanmar
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2021)

Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine
por: Hills, Susan L., et al.
Publicado: (2021)

Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine
por: Wijesinghe, Pushpa Ranjan, et al.
Publicado: (2016)

Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2
por: Li, Shi-Hua, et al.
Publicado: (2013)

Chimeric Japanese Encephalitis Virus SA14/SA14-14-2 Was Virulence Attenuated and Protected the Challenge of Wild-Type Strain SA14
por: Huang, Rong, et al.
Publicado: (2019)

Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus
por: Saga, Ryohei, et al.
Publicado: (2016)

Immunogenicity & safety of a single dose of live-attenuated Japanese encephalitis vaccine SA 14-14-2 in adults
por: Khan, Siraj Ahmed, et al.
Publicado: (2016)

Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal
por: Upreti, Shyam Raj, et al.
Publicado: (2017)

An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia
por: Hills, Susan L., et al.
Publicado: (2022)

The structure differences of Japanese encephalitis virus SA14 and SA14-14-2 E proteins elucidate the virulence attenuation mechanism
por: Liu, Xinyu, et al.
Publicado: (2018)

A randomized study of the immunogenicity and safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in comparison with SA14-14-2 Vaccine in children in the Republic of Korea
por: Kim, Dong Soo, et al.
Publicado: (2014)

The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
por: Kwon, Hyo Jin, et al.
Publicado: (2015)

A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice
por: Li, Na, et al.
Publicado: (2020)

Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area
por: Turtle, Lance, et al.
Publicado: (2017)

Amino Acid at Position 166 of NS2A in Japanese Encephalitis Virus (JEV) Is Associated with In Vitro Growth Characteristics of JEV
por: Tajima, Shigeru, et al.
Publicado: (2020)

Characteristics of Chimeric West Nile Virus Based on the Japanese Encephalitis Virus SA14-14-2 Backbone
por: Li, Guohua, et al.
Publicado: (2021)

Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain
por: Zheng, Xiaoyan, et al.
Publicado: (2020)

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine
por: Wang, Ran, et al.
Publicado: (2020)

Molecular and serological epidemiology of Japanese encephalitis virus (JEV) in a remote island of western Japan: an implication of JEV migration over the East China Sea
por: Yoshikawa, Akira, et al.
Publicado: (2016)

Immunogenicity and Protective Ability of Genotype I-Based Recombinant Japanese Encephalitis Virus (JEV) with Attenuation Mutations in E Protein against Genotype V JEV
por: Tajima, Shigeru, et al.
Publicado: (2021)

Perspectives Regarding the Risk of Introduction of the Japanese Encephalitis Virus (JEV) in the United States
por: Oliveira, Ana R. S., et al.
Publicado: (2020)

The Infection of the Japanese Encephalitis Virus SA14-14-2 Strain Induces Lethal Peripheral Inflammatory Responses in IFNAR Deficiency Mice
por: Liu, Juan, et al.
Publicado: (2022)

Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
por: Hunsawong, Taweewun, et al.
Publicado: (2017)

A Molecularly Cloned, Live-Attenuated Japanese Encephalitis Vaccine SA(14)-14-2 Virus: A Conserved Single Amino Acid in the ij Hairpin of the Viral E Glycoprotein Determines Neurovirulence in Mice
por: Yun, Sang-Im, et al.
Publicado: (2014)

Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test
por: Lee, Hee-Jung, et al.
Publicado: (2014)

Effectiveness of introduction of JEV vaccination into routine immunization program in a tribal district of Odisha
por: Kshatri, Jaya S., et al.
Publicado: (2022)

Correction: A Molecularly Cloned, Live-Attenuated Japanese Encephalitis Vaccine SA(14)-14-2 Virus: A Conserved Single Amino Acid in the ij Hairpin of the Viral E Glycoprotein Determines Neurovirulence in Mice
Publicado: (2014)

Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain
por: Sarkar, Arindam, et al.
Publicado: (2013)

Envelope Protein Mutations L107F and E138K Are Important for Neurovirulence Attenuation for Japanese Encephalitis Virus SA14-14-2 Strain
por: Yang, Jian, et al.
Publicado: (2017)

The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control
por: Vannice, Kirsten S., et al.
Publicado: (2021)

The 5′ and 3′ Untranslated Regions of the Japanese Encephalitis Virus (JEV): Molecular Genetics and Higher Order Structures
por: Liu, Hong, et al.
Publicado: (2021)

Insights into the evolutionary history of Japanese encephalitis virus (JEV) based on whole-genome sequences comprising the five genotypes
por: Gao, Xiaoyan, et al.
Publicado: (2015)

Prevalence and risk factors of Japanese encephalitis virus (JEV) in livestock and companion animal in high-risk areas in Malaysia
por: Kumar, Kiven, et al.
Publicado: (2017)

Outcome of Japanese Encephalitis Virus (JEV) Infection in Pediatric and Adult Patients at Mahosot Hospital, Vientiane, Lao PDR
por: Mayxay, Mayfong, et al.
Publicado: (2021)

Functional assignment to JEV proteins using SVM
por: Sahoo, Ganesh Chandra, et al.
Publicado: (2008)

Japanese Encephalitis Virus (JEV) NS1′ Enhances the Viral Infection of Dendritic Cells (DCs) and Macrophages in Pig Tonsils
por: Xie, Shengda, et al.
Publicado: (2022)

Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?
por: Turtle, Lance, et al.
Publicado: (2019)

Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells
por: Hunsawong, Taweewun, et al.
Publicado: (2015)

The chimeric Japanese encephalitis/Dengue 2 virus protects mice from challenge by both dengue virus and JEV virulent virus
por: Yang, Jian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6sdjqj9g36t8unipe6p2vt04pa